NantHealth
9920 Jefferson Boulevard,
Culver City
California
90232
United States
Website: http://nanthealth.com/
78 articles about NantHealth
-
NantHealth and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports
11/17/2020
NantHealth and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports Study demonstrates the viability and value of RNA sequencing from formalin fixed samples in gaining a deeper understanding of patient disease biology and in delivering diagnostic, prognostic, and therapeutic value in a clinical setting
-
Combination of Deep-Learning Models Provides Significant Risk-Assessment of Survival in Pancreatic Cancer Patients, Holding Promise as a Prognostic Technology
10/13/2020
NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, presented virtually with NantOmics and ImmunityBio on September 29-30 2020, a session entitled “ Deep-learning image-based tumor, stroma and lymphocytes spatial relationships and clinical featu
-
NantHealth Enhances Interoperability of the NaviNet Open Platform With Expanded API Capabilities
9/23/2020
Move Reinforces NantHealth’s Commitment to Improved Connectivity For Payers, Providers, and Revenue Cycle Organizations
-
NantHealth Reports 2020 Second Quarter Financial Results
8/6/2020
NantHealth, Inc., a next-generation, evidence-based, personalized healthcare company, reported financial results for its second quarter ended June 30, 2020.
-
NantHealth Acquires OpenNMS, the World’s Largest Open Source Network Management Application Platform
7/27/2020
NantHealth, Inc., a next-generation, evidence-based, personalized healthcare company, announced the acquisition of The OpenNMS Group, Inc., the world’s premier open-source network management company, which will operate as a subsidiary of NantHealth.
-
NantHealth Announces Research Results that Advances Understanding of Tumor Treatment Resistance
6/25/2020
Study Published in JCI Insight sheds light on the importance of using both transcriptomics and genomics for patient tumor interrogation to gain actionable insight CULVER CITY, Calif.--( BUSINESS WIRE )-- NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the publication of a study in JCI Insight , a peer-reviewed journal dedicated to biomedical research from preclinical to clinica
-
NantHealth Presented Clinical Data on Immunotherapy, Molecularly Targeted Agents and Tumor Biology at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
6/18/2020
NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced the publication of four abstracts on developmental therapeutics for immunotherapy, molecularly targeted agents and tumor biology during the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.
-
NantHealth to Exhibit at Virtual America’s Health Insurance Plans (AHIP) Institute & Expo 2020 with Webinars to Follow
6/16/2020
NantHealth Announces Eviti Product Updates to Aid Efficiency and Reporting for Payers & NaviNet Product Updates to Enhance the User Experience
-
In Recognition of the Challenges Providers Are Facing, NantHealth is Offering Free Access to NaviNet AllPayer for a Limited Time
5/8/2020
Providers to benefit from free access to leading payer-provider collaboration platform through May
-
NantHealth Reports 2020 First Quarter Financial Results
5/7/2020
NantHealth, Inc., a next-generation, evidence-based, personalized healthcare company, reported financial results for its first quarter ended March 31, 2020.
-
NantHealth to Report 2020 First-quarter Financial Results and Host Conference Call on Thursday, May 7
5/4/2020
NantHealth, Inc., a next-generation, evidence-based, personalized healthcare company, announced that it will report financial results for its 2020 first quarter on Thursday, May 7, 2020, after market close.
-
NantHealth Reports 2019 Fourth-quarter, Full-year Financial Results
2/28/2020
NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today reported financial results for its fourth quarter and full year ended December 31, 2019.
-
NantHealth’s Cancer Therapy Pre-Authorization Platform Eviti Connect® Starts 2020 Strong with Two Expanded Programs
2/27/2020
Continued Relationships with Health Insurers Reflect the Need for High-quality, High-value Care as Cancer Treatments Become Increasingly Complex
-
Dr. Patrick Soon-Shiong to Deliver Keynote at HIMSS 2020 Intelligent Health™ Pavilion
2/25/2020
NantHealth Chairman and CEO Will Reveal How Advancements in AI and Machine Learning are Improving the Diagnosis and Treatment of Cancer
-
NantHealth to Report 2019 Fourth-Quarter Financial Results and Host Conference Call on Friday, February 28
2/24/2020
NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2019 fourth quarter on Friday, February 28, 2020, after market close
-
NantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of Breast Cancer From Digital Pathology Images
2/19/2020
Feb. 19, 2020 13:00 UTC Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance CULVER CITY, Calif.--( BUSINESS WIRE )-- NantOmics, LLC , the leader in molecular analysis, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the publication of a peer-reviewed stu
-
NantHealth and NantOmics Reveal a Novel AI Based Machine-Learning Digital Pathology Software for Lung Cancer by Identifying Tumor Infiltrating Killer Cells From Whole Slide Images
1/28/2020
Derived from deep-learning models, the findings demonstrate novel AI methods of identifying tumor-infiltrating lymphocytes (TILs) in lung cancers
-
Data from NantHealth’s GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients
1/25/2020
NantHealth Presented These Findings at the ASCO 2020 Gastrointestinal Cancers Symposium
-
Masimo to Acquire Connected Care Business from NantHealth
1/14/2020
Masimo will acquire the Connected Care assets from NantHealth, Inc. for a $47.25 million upfront cash payment.
-
NantHealth Presents Research Demonstrating Real World Evidence of Simultaneous Presentation and Publication of Oncology Data at the 2019 San Antonio Breast Cancer Symposium
12/11/2019
Eviti Connect study showed an increase in clinical uptake of practice-changing data